Compare Illumina, Inc. (ILMN) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Snowflake Inc — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while Snowflake Inc trades at $272.55 (market cap $95.09B). The key difference: Snowflake Inc is far larger — about 3.4× Illumina, Inc.'s market cap. Which is the better fit depends on your goals.
| ILMN | SNOW | |
|---|---|---|
Market Cap | $27.94B | $95.09B |
Sector | Health | Technology |
52-Week High | $194.33 | $280.16 |
52-Week Low | $91.00 | $121.11 |
Enterprise Value | $29.33B | $94.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Snowflake (SNOW) trades at $274.09, up 1.93% with bullish technical indicators and strong analyst support. The stock shows consistent earnings beats with Q1 2026 EPS of $0.39 exceeding expectations of $0.3193. Revenue growth remains robust at $3.63 billion in 2025, though the company continues to operate at a net loss of -$1.29 billion. Technical analysis indicates bullish momentum with current price near resistance at $274, while institutional sentiment remains positive with 81% buy ratings.
Snowflake presents a growth investment opportunity with accelerating AI Data Cloud adoption and 30% revenue growth targets, but faces significant execution risks from persistent losses and intense cloud competition. The consensus price target of $299.58 suggests 9% upside potential, though profitability challenges and high valuation multiples require careful monitoring of margin improvement trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
